The role of biomarkers in detecting early changes relating to exposure to occupational carcinogens

Journal of Occupational Health

Volumn 38, Issue 4, 1996, Pages 170-178

  Shaham, Judith ^a   Ribak, Joseph ^b  

^a LOEWENSTEIN REHABILITATION HOSPITAL   (Israel)

^b NONE

Author keywords

Biological monitoring; Biomarkers; Markers of biological effective dose; Markers of biological response; Markers of internal dose; Molecular epidemiology

Indexed keywords

EID: 0042949995     PISSN: 13419145     EISSN: None     Source Type: Journal    
DOI: 10.1539/joh.38.170     Document Type: Review

References (111)

1. Jones RD, Smith DM, Thomas PG. A mortality study of vinyl chloride monomer workers employed in the United Kingdom in 1940-1974. Scand J Work Environ Hlth 1988; 14: 153-160.
2. Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos workers: Implications for models of carcinogenesis and risk assessment. Br J Cancer 1982; 45: 124-135.
3. Doll R, Peto R. The causes of cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today. New York: Oxford University Press, 1981.
4. Wynder EL, Gori GB. Contribution of the environment to cancer incidence: an epidemiological exercise. J Natl Cancer Inst 1977; 58: 825-832.
5. Silverman DT, Levin LI, Hoover RN, Harge P. Occupational risk of bladder cancer in the United States. I. White men. J Natl Cancer Inst 1989; 81: 1472-1480.
6. Silverman DT, Levin LI, Hoover RN, Harge P. Occupational risk of bladder cancer in the United States. II. Nonwhite men. J Natl Cancer Inst 1989: 81: 1480-1483.
7. Huuskonen MS. Screening for occupational cancer. Scand J Work Environ Hlth 1992; 18 (suppl): 110-114.
8. Berenblum I. The mechanism of carcinogenesis: A study of the significance of carcinogenic action related phenomena. Cancer Res 1941; 1: 807-814.
9. Mottram JC. The origin of tar tumours in mice, whether from single cells or many cells. J Pathol 1935; 40: 407-409.
10. Rous P, Beard JW. The progression to carcinoma of virus-induced rabbit papillomas (shape). J Exp Med 1935; 62: 523-548.
11. Foulds L. The experimental study of tumor progression: A review. Cancer Res 1954; 14: 327-333.
12. Case RAM, Hosker ME, McDonald DB, Pearson JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine and beta-naphthylamine. Br J Ind Med 1954; 11: 75-104.
13. Bishop JM. The molecular genetics of cancer. Science 1987; 235: 305-311.
14. Heim S, Johansson B, Mertens F. Constitutional chromosome instability and cancer risk. Mutat Res 1989; 221: 35-51.
15. Harris CC, Antrup H, Stoner G. Metabolism of benzo (a) pyrene in cultured human tissue and cells. In: Stoner G, Gelboin HV, T'So PP, eds. Polycyclic Hydrocarbons and Cancer Vol 2. New York: Academic Press, 331-342.
16. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia telangiectasia. N Engl J Med 1987; 316: 1289-1294.
17. Frunklin H, Levy BS. Carcinogens. In: Levy BS, Wegman DH, eds. Occupational health. Recognizing and preventing work related disease. Boston: Little, Brown Co., 1988: 215-227.
18. Pott P. Chirurgical observation relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of rupture, and the mortification of the toes and feet. London: Hawkes, Clark and Collins, 1775.
19. Pitot HC. Principles of carcinogenesis: chemical. In: De Vita VT, Hellman S, Rosenberg SA, eds. Principles and practice of oncology. Philadelphia: JB Lippincott, 1989: 116-135.
20. Sorsa M. Somatic mutation theory. J Toxicol Environ Health 1980; 6: 977-982.
21. Hermo H. Chemical carcinogenesis: tumor initiation and promotion. Occup Med: State of the Art Rev 1987; 2: 1-27.
22. Perera FP. Molecular cancer epidemiology : A new tool in cancer prevention. J Natl Cancer Inst 1987; 78: 887-989.
23. Miller JA. Carcinogenesis by chemicals : An overview - G.A.A. Clowes Memorial Lecture. Cancer Res 1970; 30: 559-576.
24. Hertzog PG, Smith JRL, Garner RC. Production of monoclonal antibodies to guanine imidazole ring opened aflatoxin BI-DNA, the persistent DNA adduct in vivo. Carcinogenesis 1982; 8: 825-828.
25. Weinstein IB. The scientific basis for carcinogen detection in primary cancer prevention. J Natl Cancer Inst 1981; 47: 1133-1141.
26. Pelkonen O, Vahakangas K, Nebert DW. Binding of polycyclic aromatic hydrocarbons to DNA: comparison with mutagenesis and tumorigenesis. Toxicol. Environ. Hlth 1980; 6: 1009-1020.
27. Dipple A, Micheijda CJ, Weisberger EK. Metabolism of chemical carcinogens. Pharmacol Ther 1985; 27: 265.
28. Hsieh LL, Jeffrey AM, Santella RM. Monoclonal antibodies to 1-aminopyrene-DNA. Carcinogenesis 1985; 6: 1289-1293.
29. Perera FP, Hemminki K, Young TL, Brenner D, Kelly G, Santella RM. Detection of polycyclic aromatic hydrocarbons - DNA adducts in white blood cells of foundry workers. Cancer Res 1988; 48: 2288-2291.
30. Neumann HG. The role of DNA damage in chemical carcinogenesis of aromatic amines. J. Cancer Res Clin Oncol 1986; 112: 100-106.
31. Beland FA, Fullerton NF, Kinouchi T, Poirer MC. DNA adduct formation during continuous feeding of 2 -acetylamino-fluorene at multiple concentrations. In: Bartsch H, Hemminki K, O'Neill IK, eds. Methods for detecting DNA damaging agents in humans: Applications in cancer epidemiology and prevention. IARC Scientific Publication #89. Lyon: IARC, 1988: 175-180.
32. Harris C. Chemical and physical carcinogenesis : advances and perspectives for the 1990s. Cancer Res 1991; 51: 5023-5044.
33. Aaronson S. Growth factors and cancer. Science 1991; 254: 1146-1153.
34. Weinstein IB. Cellular targets and host genes in multistage carcinogenesis. Fed Proc 1984; 43: 2287.
35. Strickland PT, Routeledge MN, Dipple A. Methodologies for measuring of carcinogen adducts in humans. Cancer Epidemiol Biomarkers Prev 1993; 2: 2607-2619.
36. 32P-postlabeling assay. Carcinogenesis 1992; 13: 1053-1074.
37. Phillips DH, Castegnaro M, Bartsh H., eds. Post-labelling Methods for Detection of DNA Adducts. IARC Scientific Publication No. 124. Lyon: IARC, 1993.
38. Phillips, D. Modern methods of DNA adduct determination. In: Cooper E, Grover P, eds. Chemical carcinogenesis and mutagenesis I. Berlin, Heidelberg: Springer-Verlag. 1990: 503-546.
39. Santella R. Application of new techniques for the detection of carcinogen adducts to human population monitoring. Mutat Res 1988; 205: 271-282.
40. Bartsch H, Kadlubar F, O'Neill, eds. Biomarkers in human cancer. Part II. Exposure monitoring and molecular dosimetry. Environ Health Perspect 1993; 99: 2-309.
41. Tornqvist M, Landin HH. Hemoglobin Adducts for In Vivo Dose Monitoring and Cancer Risk Estimation. J. Occup Environ Med 1995; 37: 1077-1084.
42. Perera F, et al. Detection of polycyclic aromatic hydrocarbon-DNA adducts in white blood cells of foundry workers. Cancer Res 1988; 48: 2288-2291.
43. Hewer A. Detection of polycyclic aromatic hydrocarbon-DNA adducts in white blood cells from coke oven workers : correlation with job categories. Cancer Res 1992; 52: 1510-1514.
44. Hemminki K, Randerath K, Reddy MV, et al. Post-labeling of immunoassay of polycyclic aromatic hydrocarbons adducts of deoxyribonucleic acid in white blood cells of foundry workers. Scand J Work Environ Health 1990; 16: 158-162.
45. Haugen A, Becher G, Benestad C, et al. Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a) pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke-oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res 1986; 46: 4178-4183.
46. Cohen GM. Mehta R, Meredith-Brown M. Large interindividual variations in metabolism of benzo (alfa) pyrene by peripheral lung tissue from lung cancer patients. Int J Cancer 1979; 24: 129-133.
47. Siedergard J, Voracheck WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on transstilbene oxide are due to a gene deletion. Proc Natl Acad Aci (USA) 1988; 85: 7293-7297.
48. Oesch F, Aulmann W, Platt KL, Doerjer D. Individual differences in DNA repair capacities in man. Arch Toxicol 1987; (Suppl) 10: 172-179.
49. 7-alkylguanine adducts by immunochemical methods and HPLC with electrochemical detection: applications in animal studies and in monitoring human exposure to alkylating agents. Environ Health Perspect 1993; 99: 25-32.
50. Shuker D, Prevost V, Friesen MD, Lin D, Ohshima H, Bartsch H. Urinary markers for measuring exposure to endogenous and exogenous alkylating agents and precursors. Environ Health Perspect 1993; 99: 33-37.
51. Autrup H, Seremet, Wakhishi J, Wasunna A. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adducts and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res 1987; 47: 3430-3433.
52. 4 in synchronous and asynchronous cultured mammalian cells. Mol Pharmacol 1986; 29: 606-613.
53. Tsapakos MJ, Hampton TH, Wetterhahn KE. Chromium VI induced DNA lesions and chromium distribution in rat kidney, liver and lung. Cancer Res 1983; 43: 5662-5667.
54. Shaham J, Bomstein Y, Melzer A, Kaufman Z, Palma E, Ribak J. DNA - protein crosslinks, a biomarker of exposure to formaldehyde - in vitro and in vivo studies. Carcinogenesis 1996; 17: 121-125.
55. Hulka SB. Overview of biological marker. In: Hulka BS, Wilcosky TC, Griffin JD, eds. Biological markers in epidemiology. Oxford: Oxford University Press, 1990: 3-15.
56. De Klein A. Oncogene activation by chromosomal rearrangement in chronic myelocytic leukemia. Mutat Res 1987; 86: 162-172.
57. Heim S, Mitelman F. Nineteen of 26 cellular oncogenes precisely localized in the human genome map to one of the 83 bands involved in primary cancer specific rearrangements. Hum Genet 1987; 75: 70-72.
58. Weinberg RA. The genetic origins of human cancer. Cancer 1988; 61: 1963-1968.
59. Allen JW, Sharief Y, Langenbach R, Waters MD. Tissue-specific sister chromatid exchange analyses in mutagen-carcinogen exposed animals. In: Langenbach R, Nesnow S, Rice JM, eds. Organ and species specificity in chemical carcinogenesis, New York: Plenum, 1983: 451-452.
60. National Toxicology Program (NTP). Board of Scientific Counselors: Report of the Ad Hoc Panel on chemical carcinogenesis testing and evaluation. August 17.
61. Carrano AV. Chromosomal alterations as a marker of exposure and effect. J Occup Med 1986; 28: 1112 -1116.
62. Lambert B, Lindblad A, Holmberg K, Francesconi D. The use of sister chromatid exchange to monitor human population for exposure to toxicologically harmful agents. In: Wolff S, ed. Sister Chromatid Exchange. New York: Wiley, 1982:149-182.
63. Gebhart E, Losing J, Wopfner F. Chromosome studies on lymphocytes in patients under cytostatic therapy. I. Conventional chromosome studies in cytostatic interval therapy. Hum Genet 1980; 55: 53-63.
64. Pohlova H, Cerna M, Rossner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res 1986; 174: 213-217.
65. Laurent C. SCE increases after an accidental acute inhalation exposure to ETO and recovery to normal after 2 years. Mutat Res 1988; 204: 711-717.
66. Stolley PD, Soper KA, Galloway SM, Nicholas WW, Norman SA, Wolman S. Sister chromatid exchange in association with occupational exposure to ethylene oxide. Mutat Res 1984; 129: 89-102.
67. Yager JW, Hines CJ, Spear RC. Exposure to ethylene oxide at work increases sister chromatid exchange in human peripheral lymphocytes. Science 1983; 219: 1221-1223.
68. Nagaya T. No increase in sister chromatid exchange frequency in lymphocytes of chromium platers. Mutat Res 1986; 170: 129-132.
69. Hansteen IL, Hillestad L, Thiis-Everseen E, Storetredt Heldaas S. Effects of vinyl chloride in man. A cytogenetic follow-up study. Mutat Res 1978; 51: 271-278.
70. Anderson D, Richardson CR, Wright TM, Purchase IFH, Adams WGF. Chromosomal analysis in vinyl chloride exposed workers. Results from analysis 18 and 42 months after the initial sampling. Mutat Res 1980; 79: 151-162.
71. Sarto F, Cominata J, Pinton AM, et al. Cytogenetic damage in workers exposed to ethylene oxide. Mutat Res 1984; 138: 185-195.
72. Bishop JM. Molecular themes in oncogenes. Cell 1991; 64: 235-248.
73. Weinstein IB. Growth factors, oncogenes, and multistage carcinogenesis. J Cell Biochem 1987; 33: 213-224.
74. Pimental E. Oncogenes. Boca Raton, FL: CRC Press, 1989.
75. Slamon DJ, De Kernion JB, Verma IM, Cline MJ. Expression of cellular oncogenes in human malignancies. Nature ( Lond.) 1984; 224: 256-262.
76. Sukumara S, Pulciani S, Doninger J, et al. A transforming ras gene in tumorigenic guinea pig cell lines initiated by diverse chemical carcinogens. Science 1984; 223: 1197-1199.
77. Balmain A, Pragnell B. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature (Lond.) 1983; 303: 72-74.
78. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A, McGuire WL. Human breast cancer: Correlations of relapse and survival with amplification of the HER-2/new oncogene. Science 1987; 235: 177-182.
79. Barbacid M. Ras gene. Ann Rev Biochem 1987; 56: 779-827.
80. 21 ras gene products among historical subtypes of fresh primary human lung tumors. Cancer Res 1986; 46: 1530-1534.
81. Gosney JR, Field JK, Gosney MA, Lye MDW, Spandidos DA, Butt SA. C-myc oncoproteins in bronchial carcinoma: Expression in all major morphological types. Anticancer Res 1990; 10: 623-628.
82. 21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med 1985; 161: 1213-1218.
83. Kotake T, Saikis S, Kinouchi T, Shiku H, Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res 1990; 81: 1198-1201.
84. Field JK, Spandidos DA. The role of ras and myc oncogenes in human solid tumors and their relevance in diagnosis and prognosis. Anticancer Res 1990; 10: 1-22.
85. Spandidos DA, Kerr JB. Elevated expression of the human ras oncogene family in premalignant and malignant tumors of the colorectum. Br J Cancer 1984; 49: 681-688.
86. Koutselini H, Kappatou G, Yiagnisis M, Field JK, Spandidos DA. Immunocytochemical study of ras oncoprotein in cytologic specimens of primary lung tumors. Anticancer Res 1990; 10: 597-604.
87. 53 inn. Nature 1993; 365: 17-18.
88. 53 alteration in human cancer: A review. Int J Cancer 1994; 57: 1-9.
89. 53 mutations in human cancer. Science 1991; 253: 49-53.
90. 53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327.
91. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-1146.
92. Crawford L, Pim DC, Ruldrook RD. Detection of antibodies against the cellular protein p 53 in sear from patients with breast cancer. Int J Cancer 1982; 30: 403-408.
93. Sozzi G, Miozzo M, Donghi R, et al. Deletions of p 17 and p 53 mutations in preneoplastic lesions of the lung. Cancer Res 1992; 52: 6079-6082.
94. 53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992; 7: 1989-1997.
95. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
96. Westra WH, Slebos RJ, Offerhaus GJ, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993; 72: 432-438.
97. Hruban RH, van der Riet P, Erozan YS, et al. Molecular biology and the early detection of carcinoma of the bladder - the case of Hubert H. Humphrey. N Engl J Med 1994; 330: 1276-1278.
98. 53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-4831.
99. Vogelstein B, Kinzler KW. Carcinogens leave fingerprints. Nature 1992; 355: 209-210.
100. Marion MJ, Froment O, Trepo C. Activation of K-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog 1991; 4: 450-454.
101. Taylor JA, Sandler DP, Bloomfield CD, et al. Ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992; 84: 1626-1632.
102. 53 mutations at A: T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994; 15: 1-3.
103. 53 mutation hot spot in radon-associated lung cancer. Lancet 1994; 343: 86-87.
104. International Agency for Research on Cancer. IARC Monogr Eval Carcinog Risk Chem Hum 1987; (sppl 7): 373-376.
105. Barbin A, Besson F, Perrard MH, et al. Induction of specific base-pair substitutions in E. coli trpA mutants by chloroethylene oxide, a carcinogenic vinyl chloride metabolite. Mutat Res 1985; 152: 147-156.
106. Shields PG, Harris CC. Molecular epidemiology and the genetics of environmental cancer. JAMA 1991; 266: 681-687.
107. National Institure for Occupational Safety and Health. Preventing lead poisoning in construction workers. Department of Health and Human Services, DHHS (NIOSH). Publ. No. 91-116, 1991.
108. Dellarco VL, Generoso WM, Sega GA, Fowle JR, III, Jacobson-Kram D. Review of the mutagenicity of ethylene oxide. Environ Mol Mutagen 1990; 16: 95-103.
109. Sarto F, Tornqvist MA, Tomanin R, Bartolucci GB, Osterman-Golkar M, Ehrenberg L. Studies of biological and chemical monitoring of low-level exposure to ethylene oxide. Scand J Environ Health 1991; 119: 60-64.
110. Mayer J, Warburton D, Jeffrey AM, et al. Biologic markers in ethylene oxide exposed workers and controls. Mutat Res 1991; 248: 163-176.
111. Schulte PA, Boeniger M, Walker JT, et al. Biological markers in hospital workers exposed to low levels of ethylene oxide. Mutat Res 1992; 278: 237-251.